Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TJ 100

Drug Profile

TJ 100

Alternative Names: Dai-kencho-to; Dai-kenchu-to; TU-100

Latest Information Update: 26 Sep 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tsumura
  • Class Anti-inflammatories; Herbal medicines; Laxatives
  • Mechanism of Action Acetylcholine stimulants; Motilin stimulants; Serotonin 3 receptor agonists; Serotonin 4 receptor agonists; Substance P stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Irritable bowel syndrome; Postoperative ileus
  • Phase III Constipation
  • Phase II Crohn's disease

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 06 Sep 2017 TJ 100 is still in phase II development for Irritable bowel syndrome in USA and phase III development for Constipation in Japan (Tsumura pipeline, September 2017)
  • 01 May 2017 Tsumara completes a phase II trial for Postoperative ileus in USA (NCT02232893)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top